{
    "nctId": "NCT01151046",
    "briefTitle": "Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer",
    "officialTitle": "A Randomized Double-Blind Phase 2 Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+) Her2 Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Her2 Negative Breast Cancer Patients",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 118,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced or metastatic breast cancer\n* Histologically or cytologically confirmed ER+ and/or PgR+ and Her2 negative breast cancer\n* \u2265 18 years of age\n\nExclusion Criteria:\n\n* Received prior treatment with exemestane\n* Extensive visceral disease (rapidly progressive, life-threatening metastases, including symptomatic lymphangitic metastases)\n* Symptomatic CNS disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}